

Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-232195

1



July 2019



Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and risks related to failure to obtain U.S. Food and Drug Administration clearances or approvals and noncompliance with its regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. The forward-looking statements in this presentation are made as of the date of this presentation, even if subsequently made available by Tonix on its website or otherwise. Tonix does not undertake an obligation to update or revise any forward-looking statement, except as required by law. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission (the "SEC") on March 18, 2019, and periodic reports and current reports filed with the SEC on or after the date thereof, as well as the Registration Statement on Form S-1, as filed with the SEC on July 1, 2019. All of Tonix's forward-looking statements.

2





This presentation highlights basic information about us and the offering to which this communication relates. Because it is a summary, it does not contain all of the information that you should consider before investing in our securities.

We have filed a registration statement (including a prospectus, which currently is in preliminary form) with the U.S. Securities and Exchange Commission ("SEC") for the offering to which this presentation relates. The registration has not yet become effective. Before you invest, you should read the preliminary registration statement (including the risk factors described therein) and other documents we have filed with the SEC for more complete information about us and this offering. You may access these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov.

The preliminary prospectus, dated July 1, 2019, is available on the SEC Web site at https://www.sec.gov/edgar/searchedgar/companysearch.html.

Alternatively, we or any underwriter participating in the offering will arrange to send you the preliminary prospectus and, when available, the final prospectus and/or any supplements thereto if you contact Aegis Capital Corp., 810 Seventh Avenue, 18th Floor, New York, NY 10019.

This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. The offering will only be made by means of a prospectus pursuant to a registration statement that is filed with the SEC after such registration statement becomes effective.



Offering Summary

Issuer:	Tonix Pharmaceuticals Holding Corp.
Ticker / Exchange:	TNXP / Nasdaq Global Market
Offering Size:	Approximately \$10,400,000 (excluding 15% Over-Allotment)
Securities Issued:	Common Stock
Use of Proceeds:	 Fund Phase 3 development for lead product candidate, TNX- 102 SL Advance the development of a recently in-licensed product candidate, TNX-1300 Working capital and other general corporate purposes
Sole Book-Runner:	Aegis Capital Corp.





Who we are:


- A clinical stage biopharmaceutical company dedicated to developing innovative treatments for patients and making meaningful contributions to society
- Focusing on small molecules and biologics to treat psychiatric, pain and addiction conditions as well as potential medical counter-measures to improve biodefense

What we do:

- · Target therapeutic areas with high need for improvement
 - Conditions with no, or inadequate treatments
 - Significant patient segments not well served by existing therapies
- Develop innovative treatment options
 - Scientifically unique and innovative
 - Supported by strong scientific rationale
 - Supported by preliminary clinical evidence and published literature
 - Utilize proven regulatory pathway and established clinical endpoint

TNX-102	ry, Pain and Ad SL and TNX-601		outrigh	nt with	ent no roya	alties due		6
Pipeline Product	Indication	Preclinical	Phase 1	Phase 2	Phase 3	NDA1/BLA2	Market	0
NX-102 SL ³	Bedtime Treatment for PTSD – Tonmya®4							
clobenzaprine HCl sublingual tablets tectic® formulation	Bedtime Treatment for Fibromyalgia			$ \rightarrow$				
technology	Bedtime Treatment for Agitation in Alzheimer's		$ \rightarrow $					
TNX-1300 ⁵ Cocaine esterase	Cocaine intoxication / overdose							
ombinant from bacte $\lambda v.$ formulation	ria)							
71112 604	Daytime Treatment for PTSD							
TNX-601 ianeptine oxalate ora formulation	Treatment of Neurocognitive Dysfunction from Corticosteroids							


I NDA-New Drug Application; ¹BLA -Biologic Licensing Application; ¹TNK-102 SL (cyclobenzaprine HCI sublingual tablets) is an investigational new drug and has not been approved for any indication; ¹Tormya has been conditionally accepted by the U.S. FDA as the proposed trade name for TWK-102 SL for the treatment of PTSD, ¹TWK-1300 (T172R/G173Q double-mutant occaine esterase 200 mg, i.v. solution) is an investigational new biologic and has not been approved for any indication © 2019 Tornix Pharmaceuticals Holding Corp.



NDA-New Drug Application; *BLA -Biologic Licensing Application © 2019 Tonix Pharmaceuticals Holding Corp.

b Ma	inagement Team	8
	Seth Lederman, MD President & CEO	TARGENT Fusilev vela
	Gregory Sullivan, MD Chief Medical Officer	COLUMBRA UNIVERSITY New York State Department of Psychiatry Psychiatric Institute
	Bradley Saenger, CPA Chief Financial Officer	
×	Jessica Morris Chief Operating Officer	Deutsche Bank
	© 2019	Tonix Pharmaceuticals Holding Corp.





⁴ Goldstein et al., 2016 (adjusted for 2019); "Norris, PTSD Res Quar. 2013; "Analysis of VA Health Care Utilization among Operation Enduring Freedom, Operation Iragi Freedom, and Operation New Dawn Veterans, from 1st Qtr FY 2002 through 2nd Qtr FY 2015; Washington, DC; Among 1.5M separated OEF/OIF/OND veterans, 1.2M have obtained VA healthcare; 685k evaluated by VA with possible mental disorder, and 379k diagnosed with PTSD. 2013 Tonix Pharmaceuticals Holdino Corp.

Unmet Need for Effective and Safe Therapies for Treatment of PTSD

11

No FDA-approved products for PTSD since Pfizer's Zoloft® (sertraline) and GSK's Paxil® (paroxetine) circa 2000

- · Neither has shown efficacy in military-related PTSD
- · Male PTSD patients often unresponsive or intolerant of current treatments
- Side effects relating to sexual dysfunction, sleep disruption and weight gain are commonly reported

PTSD is signature wound of last 25 years of war

- · Affects servicemember health and performance, force readiness, retention
- · Believed to be the underlying cause of suicide in many cases

First investigational new drug to show treatment effect in military-related PTSD in two potential pivotal efficacy studies

 Phase 2 study (P201/AtEase) showed Tonmya 5.6 mg had a signal of treatment effect at Week 12 as measured by CAPS-5¹ 12

- Phase 3 study (P301/HONOR) provided evidence of effectiveness as early as 4 weeks after treatment but diminished over time due to high placebo response
 - Retrospective analysis showed persistent effectiveness at Week 12 in subgroup with Time Since Trauma =9 years from screening
- Both studies can be used potentially as supportive evidence of efficacy and safety for Tonmya NDA submission
- · No serious or unexpected adverse events related to Tonmya were reported

FDA feedback and acceptance of new Phase 3 study (P302/RECOVERY) received in November 2018²

¹ CAPS-5 = Clinician-Administered PTSD Scale for DSM-5 ² FDA Meeting Minutes, November 25, 2018



Potential Therapeutic Advantages of Tonmya



Tonmya is believed to treat PTSD by improving sleep quality

- The brain naturally processes memories during sleep
- PTSD sufferers' emotionally charged memories disturb sleep and disrupt the natural processing of memories during sleep
- Tonmya is believed to normalize memory processing and facilitate extinction consolidation (breaking the link between "triggers" and PTSD symptoms)


Tonmya is NEITHER a benzodiazepine nor a narcotic

 The active ingredient of Tonmya, cyclobenzaprine, does <u>NOT</u> interact with the same receptors as traditional hypnotic sleep drugs associated with retrograde amnesia; is <u>NOT</u> an opiate


Tonmya is non-addictive


- Cyclobenzaprine is the active ingredient of an orally ingested immediate release tablet (Flexeril®), approved 40 years ago
- Flexeril's current labeling indicates no abuse and dependence concern at higher doses than Tonmya (15-30 mg/day v. 5.6 mg/day); NDA can be filed without drug abuse and dependency assessment studies

Once-daily sublingual dose taken at bedtime enhances patient adherence



¹ Completed Phase 2 P201/AtEase study: Retrospective analysis of Tonmya 5.6 mg on CAPS-5 =33 (high-moderate) subgroup. Primary analysis of P201/AtEase, based on Tonmya 2.8 mg in participants with entry CAPS-5 =29 (moderate PTSD seventy), was not statistically significant. ² CAPS-5 = CInician administered PTSD Scale for DSM-5.





1 Majority of P201 participants were = 9 years since trauma and ~80% of P201 participants and all of P301 participants were = 33 CAPS-5 at baseline

CAPS-5 = 33 group in P2011



Adverse Events (AEs) in P201/AtEase and P301/HONOR Studies

		P201	P301		
Category of Adverse Reaction Preferred Term	Placebo (N=94)	TNX 2.8 mg (N=93)	TNX 5.6 mg (N=50)	Placebo (N=134)	TNX 5.6 mg (N=134)
Systemic Adverse Events**					
Somnolence	6.4%	11.8%	16.0%	9.0%	15.7%
Dry mouth	10.6%	4.3%	16.0%		
Headache	4.3%	5.4%	12.0%		
Insomnia	8.5%	7.5%	6.0%		
Sedation	1.1%	2.2%	12.0%		
Local Administration Site Reaction	ns* [#]				
Hypoaesthesia oral	2.1%	38.7%	36.0%	1.5%	37.3%
Paraesthesia oral	3.2%	16.1%	4.0%	0.7%	9.7%
Glossodynia	1.1%	3.2%	6.0%		
Product Taste Abnormal				3.0%	11.9%

17

*only adverse events (AEs) are listed that are at a rate of = 5% in any TNX-treated group *no values in a row for either study means the AE in the active group(s) in that study was at a rate of <5%

No serious or unexpected AEs in P201 or P301 related to Tonmya

- Systemic AEs comparable between studies and also consistent with those described in approved oral cyclobenzaprine product labeling
- Severity and incidence of oral hypoesthesia (oral numbness) are not dose related and similar in both
 studies
 © 2013 Tonix Pharmaceuticals Holding Corp.

New Phase 3 P302/RECOVERY Study – Initiated 1Q 2019

18

General study characteristics:

- Randomized, double-blind, placebo-controlled study with baseline CAPS-5¹ = 33 in approximately 30 U.S. sites
- Enrollment restricted to study participants with PTSD who experienced an index trauma = 9 years from the date of screening

Both civilian and military-related PTSD to be included



Primary endpoint:

 CAPS-5¹ mean change from baseline at Week 4 (Tonmya 5.6 mg vs. placebo)

Key Secondary endpoints include:


- CAPS-5 mean change from baseline at Week 12 (Tonmya 5.6 mg vs. placebo)
- Change from baseline Clinical Global Impression Severity scale
- · Change from baseline Sheehan Disability Scale total score

Potential pivotal efficacy study to support NDA approval

CAPS-5 = Clinician-Administered PTSD Scale for DSM-5



Fibromyalgia is a Chronic, Debilitating Disorder that Imposes a Significant Societal and Economic Burden



Volkswagen Check Engine (Photograph). (2011, October 14). Wikipedia

Fibromyalgia is considered a neurobiological disorder characterized by1: chronic widespread pain, non restorative sleep, fatigue, diminished cognition

· Believed to result from inappropriate pain signaling in central nervous system in the absence of peripheral injury1

19

- Causes significant impairment in all areas of life²
- · Lower levels of health-related quality of life reduced daily functioning
- · Interference with work (loss of productivity, disability)
- Inflicts substantial strain on the healthcare system
 - Average patient has 20 physician office visits per year³

¹Philips K & Clauw DJ, Best Pract Res Clin Rheumatol 2011;25:141.
²Scheefer et al., Pain Pract, 2015.
³Robinson et al, Pain Medicine 2013;14:1400.



Currently-approved medications may have side effects that limit long-term use¹
 Many patients skip doses or discontinue altogether within months of treatment initiation

20

- · Medication-related side effects may be similar to fibromyalgia symptoms
- High rates of discontinuation, switching and augmentation
 - · Attempt to treat multiple symptoms and/or avoid intolerable side effects
 - Average of 2-3 medications used simultaneously²
 - The typical patient has tried six different medications³
- Substantial off-label use of narcotic painkillers and prescription sleep aids³
- TNX-102 SL is a non-opioid, centrally-acting analgesic that may provide a new therapeutic option for fibromyalgia patients

¹Nuesch et al, Ann Rheum Dis 2013;72:955-62. ²Robinson RL et al, Pain Medidne 2012;13:1366. ⁸Patent Trends: Ribromyalgia⁴, Decision Resources, 2011.



Recombinant protein that degrades cocaine in the bloodstream¹

Double-mutant cocaine esterase

Phase 2 study completed by Rickett Benckiser (TNX-1300 was formerly RBP-8000)²


- · Volunteer cocaine abusers received cocaine 50 mg i.v. infusion over 10 minutes
- · TNX-1300 given one minute after completion of cocaine infusion
 - Rapidly reversed the physiologic effects of cocaine; cocaine plasma exposures dropped by 90% within two minutes


21

 Well tolerated with the most frequently reported adverse events being gastrointestinal disorders (including dry mouth, nausea); nervous systems disorders (including headache, dizziness) and skin and subcutaneous tissue disorders (including hyperhidrosis, dermatitis)

*TMX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution) is an investigational new biologic and has not been approved for any indication.

¹ Gao D et al, Mol Pharmacol. 2009. 75(2): 318-23. ² Nasser AF et al, J Addict Dis, 2014;33(4):289-302.






Cocaine Intoxication

Ţ

1 Dopamine


1. Brim et al . Nol Pharmacol. 2011.

Norepinephrine
 Channel function




Pharmacotherapies for Cocaine Intoxication Have Not Been Effective

Treatments for opiates not effective for cocaine:




24




TNX-1300 (CocE) Accelerates Recovery From Cocaine Intoxication in Humans

TNX-1300 cleaves cocaine in humans and removes it from the blood circulation¹ (N=29) intoxication without inducing serious side effects¹

26





I Franciškovic T, et al. Psychiatr Danub. 2011 Sep;23(3):257-63. PMID: 21963693
 ² Rumyantseva GM and, Stepanov ML. Neurosa Behav Physol. 2008 Jan;33(1):55-61. PMID: 18097761
 ³ Acksandrovskii I.A, et al. – Th Neuro Ješkihatr Im S 5 Korsakova. 2005;105(11):24-9. PMID: 15329631 [Russian]
 ⁴ Onder E, et al. Eur Psychiatry. 2006 (3):174-9. PMID: 15964747
 [©] 2019 Tonix Pharmaceuticals Holding Corp.

TNX-801 (Synthesized Live Horsepox Virus): A Smallpox-Preventing Vaccine Candidate

-	28
Pre-IND Stage	 Potential improvement over current biodefense tools against smallpox Leverages Tonix's government affairs effort Collaboration with Professor David Evans and Dr. Ryan Noyce at University of Alberta Demonstrated protective vaccine activity in mice Patent application on novel vaccine submitted Regulatory strategy We intend to meet with FDA to discuss the most efficient and appropriate investigational plan to support approval, either: Application of the "Animal Rule", or Conducting an active comparator study using ACAM2000 Good Manufacturing Practice (GMP) viral production process in development
Targeting a Potential Public Health Issue	Material threat medical countermeasure under 21st Century Cures Act Qualifies for Priority Review Voucher (PRV) upon licensure* PRVs have no expiration date, are transferrable and have sold for ~\$125 M

*BLA/NDA priority 6-month review is expected.





🗹 November 2018	Received FDA minutes confirming agreement on the design of P302/RECOVERY study
March 2019	Met with FDA to discuss new FM Phase 3 study design using TNX-102 SL 5.6 mg
🗹 March 2019	P302/RECOVERY study initiated
🗹 April 2019	Received FDA formal minutes with clear guidance and support on new Phase 3 FM study
🗹 May 2019	In-licensed TNX-1300, product candidate in Phase 2 development for cocaine intoxication
Second Half 2019	Preliminary human pharmacokinetic and safety data (non-IND study) from selected TNX-601 (tianeptine oxalate) formulation expected
First Half 2020	Topline data from P302/RECOVERY study expected





 Tonmya for PTSD: affects 12 million adults in U.S.; currently conducting Phase 3 trial with data expected next year; bedtime treatment

30

TNX-102 SL for Fibromyalgia: affects between 5-10 million adults in U.S.; in Phase 3 development

Two Phase 2 Programs in indications for which there is no FDA-approved drug available

- TNX-1300 for Cocaine Intoxication: biologic; ready for Phase 2
- · TNX-102 SL for Agitation in Alzheimer's Disease: ready for Phase 2/3

Pipeline products to improve biodefense and leverage PTSD expertise

- TNX-601: tianeptine oxalate in formulation development for daytime treatment of PTSD
- TNX-801: smallpox-preventing vaccine in preclinical development; demonstrated protective vaccine activity in mice; GMP viral production process in development



31

Thank you!